Current landscape and tailored management of immune-related adverse events

Unprecedented advances have been made in immune checkpoint inhibitors (ICIs) in the treatment of cancer. However, the overall benefits from ICIs are impaired by the increasing incidence of immune-related adverse events (irAEs). Although several factors and mechanisms have been proposed in the develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenhui, Luo, Zhiying, Liu, Yiping, Sun, Bao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025325/
https://www.ncbi.nlm.nih.gov/pubmed/36950013
http://dx.doi.org/10.3389/fphar.2023.1078338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025325/
https://www.ncbi.nlm.nih.gov/pubmed/36950013
http://dx.doi.org/10.3389/fphar.2023.1078338

Ejemplares similares